Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution
Resmed (NYSE: RMD, ASX: RMD) announced a comprehensive brand evolution to unify its portfolio under a single identity, marking a significant shift in its 35-year history. The health technology company, focused on sleep, breathing, and home care, aims to consolidate its brands, products, and services over the next couple of years.
The rebranding includes a new visual identity, logo, and brand voice, positioning Resmed as an approachable health technology leader. This evolution coincides with three major initiatives: a U.S. consumer campaign to destigmatize CPAP therapy, a primary care physician education campaign for earlier sleep apnea diagnosis, and a sleep health awareness campaign in Asia Pacific and Europe.
According to Resmed's 2025 Global Sleep Survey, one-third of respondents report sleep difficulties, with 34% having trouble falling asleep and 29% staying asleep. The company estimates that over 2.3 billion people worldwide suffer from sleep apnea, insomnia, COPD, or other respiratory insufficiency.
Resmed (NYSE: RMD, ASX: RMD) ha annunciato una completa evoluzione del marchio per unificare il proprio portafoglio sotto un'unica identità, segnando un cambiamento significativo nella sua storia di 35 anni. L'azienda di tecnologia sanitaria, focalizzata su sonno, respirazione e assistenza domiciliare, mira a consolidare i propri marchi, prodotti e servizi nei prossimi anni.
Il rebranding include una nuova identità visiva, un logo e una voce di marca, posizionando Resmed come un leader accessibile nel settore della tecnologia sanitaria. Questa evoluzione coincide con tre iniziative principali: una campagna per i consumatori negli Stati Uniti per ridurre lo stigma sulla terapia CPAP, una campagna di formazione per medici di base per una diagnosi precoce dell'apnea del sonno e una campagna di sensibilizzazione sulla salute del sonno in Asia Pacifico e in Europa.
Secondo il Global Sleep Survey 2025 di Resmed, un terzo dei rispondenti riporta difficoltà nel sonno, con il 34% che ha problemi ad addormentarsi e il 29% a rimanere addormentato. L'azienda stima che oltre 2,3 miliardi di persone in tutto il mondo soffrano di apnea del sonno, insonnia, BPCO o altre insufficienze respiratorie.
Resmed (NYSE: RMD, ASX: RMD) anunció una evolución integral de la marca para unificar su portafolio bajo una sola identidad, marcando un cambio significativo en su historia de 35 años. La empresa de tecnología de la salud, centrada en el sueño, la respiración y el cuidado en el hogar, tiene como objetivo consolidar sus marcas, productos y servicios en los próximos años.
El cambio de marca incluye una nueva identidad visual, un logo y una voz de marca, posicionando a Resmed como un líder accesible en tecnología de la salud. Esta evolución coincide con tres iniciativas principales: una campaña para consumidores en EE. UU. para desestigmatizar la terapia CPAP, una campaña de educación para médicos de atención primaria para un diagnóstico temprano de la apnea del sueño, y una campaña de concienciación sobre la salud del sueño en Asia-Pacífico y Europa.
Según la Encuesta Global del Sueño 2025 de Resmed, un tercio de los encuestados reporta dificultades para dormir, con un 34% teniendo problemas para conciliar el sueño y un 29% para mantenerse dormido. La empresa estima que más de 2.3 mil millones de personas en todo el mundo sufren de apnea del sueño, insomnio, EPOC u otras insuficiencias respiratorias.
Resmed (NYSE: RMD, ASX: RMD)는 35년의 역사에서 중요한 변화를 나타내며 포트폴리오를 단일 정체성 아래 통합하기 위한 종합적인 브랜드 진화를 발표했습니다. 수면, 호흡 및 가정 치료에 중점을 둔 이 건강 기술 회사는 향후 몇 년 동안 브랜드, 제품 및 서비스를 통합하는 것을 목표로 하고 있습니다.
리브랜딩에는 새로운 시각적 정체성, 로고 및 브랜드 음성이 포함되어 있으며, Resmed를 접근 가능한 건강 기술 리더로 자리매김하고 있습니다. 이 진화는 세 가지 주요 이니셔티브와 동시에 진행됩니다: CPAP 치료에 대한 낙인을 줄이기 위한 미국 소비자 캠페인, 조기 수면 무호흡증 진단을 위한 1차 진료 의사 교육 캠페인, 아시아 태평양 및 유럽에서의 수면 건강 인식 캠페인입니다.
Resmed의 2025 글로벌 수면 조사에 따르면 응답자의 3분의 1이 수면에 어려움을 겪고 있으며, 34%는 잠들기 어려워하고 29%는 잠을 유지하는 데 어려움을 겪고 있습니다. 이 회사는 전 세계적으로 23억 명 이상이 수면 무호흡증, 불면증, COPD 또는 기타 호흡기 부족으로 고통받고 있다고 추정하고 있습니다.
Resmed (NYSE: RMD, ASX: RMD) a annoncé une évolution complète de sa marque pour unifier son portefeuille sous une seule identité, marquant un changement significatif dans son histoire de 35 ans. L'entreprise de technologie de la santé, axée sur le sommeil, la respiration et les soins à domicile, vise à consolider ses marques, produits et services au cours des prochaines années.
Le rebranding comprend une nouvelle identité visuelle, un logo et une voix de marque, positionnant Resmed comme un leader accessible dans le domaine de la technologie de la santé. Cette évolution coïncide avec trois initiatives majeures : une campagne auprès des consommateurs aux États-Unis pour déstigmatiser la thérapie CPAP, une campagne de formation pour les médecins généralistes pour un diagnostic précoce de l'apnée du sommeil, et une campagne de sensibilisation à la santé du sommeil en Asie-Pacifique et en Europe.
Selon l'enquête mondiale sur le sommeil 2025 de Resmed, un tiers des répondants signalent des difficultés de sommeil, 34 % ayant des problèmes pour s'endormir et 29 % pour rester endormis. L'entreprise estime que plus de 2,3 milliards de personnes dans le monde souffrent d'apnée du sommeil, d'insomnie, de BPCO ou d'autres insuffisances respiratoires.
Resmed (NYSE: RMD, ASX: RMD) hat eine umfassende Markenentwicklung angekündigt, um sein Portfolio unter einer einzigen Identität zu vereinen, was einen bedeutenden Wandel in seiner 35-jährigen Geschichte darstellt. Das Gesundheitsunternehmen, das sich auf Schlaf, Atmung und häusliche Pflege konzentriert, zielt darauf ab, in den nächsten Jahren seine Marken, Produkte und Dienstleistungen zu konsolidieren.
Das Rebranding umfasst eine neue visuelle Identität, ein Logo und eine Markenstimme, die Resmed als zugänglichen Marktführer im Gesundheitsbereich positioniert. Diese Entwicklung fällt mit drei wichtigen Initiativen zusammen: einer Verbraucher-Kampagne in den USA zur Entstigmatisierung der CPAP-Therapie, einer Aufklärungskampagne für Hausärzte zur frühzeitigen Diagnose von Schlafapnoe und einer Kampagne zur Sensibilisierung für Schlafgesundheit in Asien-Pazifik und Europa.
Laut der Global Sleep Survey 2025 von Resmed berichten ein Drittel der Befragten von Schlafproblemen, wobei 34 % Schwierigkeiten beim Einschlafen und 29 % beim Durchschlafen haben. Das Unternehmen schätzt, dass weltweit über 2,3 Milliarden Menschen an Schlafapnoe, Schlaflosigkeit, COPD oder anderen Ateminsuffizienzen leiden.
- Strategic brand consolidation to strengthen market position and streamline operations
- Launch of three major market initiatives to expand awareness and treatment adoption
- Large addressable market of 2.3+ billion potential patients globally
- None.
Insights
ResMed's brand evolution represents a strategic pivot that goes beyond cosmetic changes, signaling its transformation from a medical device manufacturer to an integrated health technology company with direct consumer engagement. This shift targets an enormous addressable market of 2.3+ billion people with sleep apnea, insomnia, COPD, and respiratory conditions.
The consolidation of multiple brands under a single ResMed identity over the next two years will likely generate operational efficiencies in marketing spend and supply chain management. More importantly, it positions ResMed to capitalize on the convergence of consumer wellness and medical treatment – a trend driving significant valuations in the health technology sector.
ResMed's three-pronged market approach is particularly astute: the U.S. consumer campaign could accelerate adoption rates by reducing therapy stigma; the physician education initiative addresses diagnostic bottlenecks; and the international awareness campaigns target untapped global markets. This comprehensive strategy suggests ResMed is pursuing both immediate market penetration and long-term category expansion.
The transition from a primarily B2B medical device company to a hybrid B2B/B2C health technology leader parallels successful transformations we've seen in other sectors. While not an immediate revenue catalyst, this repositioning strategically aligns ResMed for sustained growth toward their ambitious goal of serving 500 million people by 2030, representing substantial expansion from their current base.
Brand Evolution Unites Brands Under One Resmed Identity to Make Better Sleep and Breathing Health More Accessible to Everyone
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement.
For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions. The company’s last major brand update in 2014 marked its shift to connectivity, introducing cloud-connected medical devices that revolutionized sleep apnea therapy. Today, Resmed is taking the next step – transforming into a fully unified health technology brand that serves millions of consumers, healthcare professionals, and software users worldwide.
An estimated 2.3+ billion people worldwide suffer from sleep apnea, insomnia, COPD, or other respiratory insufficiency. 1 2 3 Additionally, Resmed’s 2025 Global Sleep Survey highlights the widespread impact of poor sleep, with one-third of respondents reporting sleep difficulties, including trouble falling asleep (
“We are at a pivotal moment in health – sleep and breathing health are gaining the attention once reserved for diet and exercise, with consumers taking a more proactive role in their care,” said Katrin Pucknat, Resmed’s Chief Marketing Officer. “Our brand evolution is more than a new look – it’s a bold step forward in our strategy to make sleep and breathing health a mainstream priority in global healthcare.”
As part of the brand evolution, Resmed plans to consolidate its brands, products, and services under a single Resmed brand over the next couple of years, creating a more streamlined view for both consumers and healthcare providers. This transformation is accompanied by a new visual identity, redesigned logo, and refreshed brand voice, reinforcing Resmed’s position as an approachable, people-centered, and forward-thinking health technology company.
The brand evolution aligns with Resmed’s mission to create life-changing health technologies that people love and coincides with three major market-facing initiatives aimed at reshaping perceptions of sleep therapy and expanding awareness of sleep apnea treatment:
- The company’s first U.S. consumer campaign aimed at destigmatizing CPAP therapy and positioning sleep health as more approachable
- A targeted primary care physician (PCP) education campaign starting in the U.S. to help drive earlier diagnosis and intervention for sleep apnea
- A sleep health awareness campaign in key markets in Asia Pacific and Europe focused on helping to overcome the barriers to seeking treatment for sleep apnea
“Resmed has evolved beyond its origins as a CPAP device and mask manufacturer. Our new brand reflects who we are today – a global leader in health technology, delivering solutions that help people rise to their full potential through better sleep and breathing, with care delivered in the home,” said Mick Farrell, Resmed’s Chairman & CEO. “With this evolution, we are reaffirming our commitment to empowering 500 million people worldwide to achieve their full health potential by 2030 and changing the delivery of healthcare.”
To learn more about Resmed’s brand evolution, visit resmed.com/brand-evolution.
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
| For Media | For Investors |
| Julia Moser | Mike Ott or Wendy Wilson |
| news@resmed.com | investorrelations@resmed.com |
_________________________________
1 Benjafield et al Lancet Respir Med 2019
2 Benjafield et al Sleep Med (suppl) 2024
3 Boers et al JAMA Network Open 2023
4 Based on over 30,000 respondents across 13 markets surveyed as part of the ResMed 2025 Global Sleep Survey between December 12-28, 2024)
FAQ
What are the main components of Resmed's (RMD) 2025 brand evolution strategy?
How many people globally are affected by conditions that Resmed (RMD) addresses?
What are the key findings from Resmed's (RMD) 2025 Global Sleep Survey?
What is Resmed's (RMD) 2030 goal for patient impact?
